PHIGENIX is a leader in developing diagnostics and targeted therapies which may assist physicians in determining treatment regime. With these diagnostic tests, prostate and breast cancer patients likely to benefit maximally from a particular therapy can be identified, and other patients for whom alternative therapies (e.g. hormonal manipulation) can be selected. We accomplish this by pioneering new approaches in early detection and targeted inhibition of PAX2 and EN2 cancer oncogenes. We are also developing a cancer vaccine that utilizes Human Beta Defensin-1 (DEFB1) mRNA to selectively target cancer cells to be destroyed by the immune system.